SOTHEMACAS:SOT -0.12%71 Days Payable is 132.59 as of Dec. 2025, which is 7% above its 10-year median of 123.67. GuruFocus rates CAS:SOT with a GF Score™ of 71/100 and a GF Value™ of MAD284.90 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 923 Drug Manufacturers companies, SOTHEMA ranks better than 68.36% on this metric.
SOTHEMA's average Accounts Payable for the
six
months ended in Dec. 2025 was MAD615 Mil. SOTHEMA's Cost of Goods Sold for the
six
months ended in Dec. 2025 was MAD847 Mil.
Hence, SOTHEMA's Days Payable for the
six
months ended in Dec. 2025 was 132.59.
The historical rank and industry rank for SOTHEMA's Days Payable or its related term are showing as below:
CAS:SOT'
s Days Payable Range Over the Past 10 Years
Min: 108.31 Med: 123.67 Max: 142.74
Current: 127.59
During the past 13 years, SOTHEMA's highest Days Payable was 142.74. The lowest was 108.31. And the median was 123.67.
CAS:SOT's Days Payable is ranked better than 68.36% of 923
companies
in the Drug Manufacturers industry
Industry Median: 90.98
vs CAS:SOT: 127.59
SOTHEMA's Days Payable
declined
from Dec. 2024 (153.65) to Dec. 2025 (132.59).
It may suggest that SOTHEMAaccelerated paying its suppliers.
SOTHEMA Days Payable Related Terms
SOTHEMA Days Payable Historical Data
* Premium members only.
The historical data trend for SOTHEMA's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAS:SOT vs LLY, JNJ, ABBV: Days Payable Comparison
For the Drug Manufacturers - General subindustry, SOTHEMA's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SOTHEMA Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SOTHEMA's Days Payable distribution charts can be found below:
* The bar in red indicates where SOTHEMA's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
SOTHEMA's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SOTHEMA (CAS:SOT) has a Days Payable of 132.59 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on SOTHEMA and its competitors. This is near median its historical median of 123.67. Over the past decade, SOTHEMA's Days Payable has ranged from 108.31 to 142.74. According to the industry distribution chart, SOTHEMA ranks #292 out of 923 companies in the Drug Manufacturers industry, placing it in the top 31.6%.
Is SOTHEMA's Days Payable too high?
SOTHEMA's current Days Payable of 132.59 is near median its 10-year median of 123.67. Over the past 10 years, this metric has ranged from a low of 108.31 to a high of 142.74. The Drug Manufacturers industry median Days Payable is 90.98. SOTHEMA's value of 132.59 is 45.7% above this industry median. Based on the distribution chart, SOTHEMA ranks #292 out of 923 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, SOTHEMA has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SOTHEMA's Days Payable compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, SOTHEMA ranks #292 out of 923 companies for Days Payable. This puts SOTHEMA in the upper half of its industry. The industry median Days Payable is 90.98. SOTHEMA's value of 132.59 is 45.7% above this benchmark. Historically, SOTHEMA's own Days Payable has ranged from 108.31 to 142.74 over the past decade. While the company's 10-year median is 123.67 vs. the industry median of 90.98, SOTHEMA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.98, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SOTHEMA's current Days Payable of 132.59 is 45.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on SOTHEMA and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SOTHEMA's current Days Payable is 132.59, which is near median its own 10-year median of 123.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SOTHEMA stock overvalued right now?
Based on GuruFocus' analysis, SOTHEMA (CAS:SOT) is currently considered Significantly Overvalued. The stock's GF Value™ is MAD284.90, compared to a current price of MAD379.50 — trading 33.2% above its estimated fair value. The current Days Payable is 132.59, which is near median its 10-year median of 123.67 and 45.7% above the Drug Manufacturers industry median of 90.98. SOTHEMA's overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For SOTHEMA (CAS:SOT), the current Days Payable is 132.59 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SOTHEMA (CAS:SOT) Overvalued in 2026?
Based on GuruFocus' analysis, SOTHEMA stock appears to be overvalued.
The current stock price of MAD379.50 is trading 33.2% above its estimated GF Value™ of MAD284.90.
GuruFocus considers SOTHEMA to be Significantly Overvalued.
Key valuation signals for CAS:SOT:
Days Payable: 132.59 (near median its 10-year median of 123.67)
GF Value™: MAD284.90 vs. price of MAD379.50 (33.2% above fair value)
Industry Position: 45.7% above the Drug Manufacturers median (#292 of 923)
No single metric tells the full story. See the CAS:SOT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SOTHEMA engages in representation, purchase and sale of pharmaceutical, chemical, health-related, biological, veterinary, plant-based, cosmetic and scented products. The company sells its products in Morocco and overseas.
71GF Score
Get the complete analysis for CAS:SOT
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAS:SOT has been successfully added to your 
